Potenza becomes ... Werewolf?

Startup Potenza Therapeutics was acquired this past winter by the Japanese drug maker Astellas for a cool $165 million. Now much of Potenza's staff is back but under a new umbrella: Werewolf Therapeutics. The cancer immunotherapy company, whose technology remains under lock and key, broadly reveals that it’s working on “more targeted drugs that target immune activators to the tumor — and this is going to be in a very different way than anyone’s done before.” 

As we await a more comprehensive explanation of the science, we wonder: Why the lycanthropic moniker?

“They come up with weird names,” laughed one scientific adviser. “Potenza was a tire, man.”

Read more.